Offline dengan aplikasi Player FM !
Nested, Cellarity, Replimune, Estrella
Manage episode 343695593 series 2833924
Biotech’s with a series A, a series C, some debt financing, and there is even a Biopharma heading for a SPAC
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Nested Therapeutics
Cellarity
Replimune
Estrella Biopharma
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
72 episode
Manage episode 343695593 series 2833924
Biotech’s with a series A, a series C, some debt financing, and there is even a Biopharma heading for a SPAC
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Nested Therapeutics
Cellarity
Replimune
Estrella Biopharma
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
72 episode
Όλα τα επεισόδια
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.